Organoid-based evaluation of SA55 and Pemivibart against evolving SARS-CoV-2 variants
Zhixin Wan(University of Hong Kong), Jie Zhou, Xinjie Meng, Yidong Yang(University of Science and Technology of China), Shuxin Zhang(Beijing Jiaotong University), Zijun Zhao(University of Hong Kong), Yunlong Cao, Xiaoxin Zhu, Wei Xue, Xiang Gao, Hin Chu, Man Chun Chiu, Jingjing Huang, Yifei Yu, Jiali Wu, Cun Li, Yuhong Liu, Ying Zhou, Fanchong Jian(Pioneer (United States)), Lin Huang, Qiaoshuai Lan(Chinese University of Hong Kong)
Cited by 0
Related Papers
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
|Signal Transduction and Targeted Therapy|2020|363
Squalene epoxidase drives NAFLD-induced hepatocellular carcinoma and is a pharmaceutical target
|Science Translational Medicine|2018|285